As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing ...
BioSpace's 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved ...
Constructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical ...
Looking for a clinical job? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Every biopharma R&D and investment decision could be guided by connected intelligence. Join us to hear firsthand how agentic workflows and enterprise-scale data are helping drug developers move faster ...
Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors.
Icotyde is backed by data from the Phase 3 ICONIC program which, among other advantages, showed significant superiority over Bristol Myers Squibb’s Sotyktu.
Alongside R1 Therapeutics, Mestag Therapeutics and iDEL Therapeutics also brought in money on Tuesday, helping to push their respective cancer portfolios forward.
Heath Secretary Robert F. Kennedy Jr.’s efforts to overhaul vaccine policy are likely illegal, a Massachusetts District Court Judge ruled; Structure’s GLP-1 weight loss pill succeeds in Phase 2 while ...
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results